Literature DB >> 14656737

Glargine and regular human insulin similarly acutely enhance endothelium-dependent vasodilatation in normal subjects.

Jukka Westerbacka1, Robert Bergholm, Mirja Tiikkainen, Hannele Yki-Järvinen.   

Abstract

OBJECTIVE: Human insulin enhances the vasodilatory effect of acetylcholine (ACh), an endothelium-dependent vasodilator, in normal subjects. Structural changes in a long-acting insulin analog, insulin glargine, may change its binding properties to insulin receptor and structurally homologous receptors, such as the insulin-like growth factor-1 receptor, and thereby alter its vascular effects. In the present study, we compared effects of glargine and regular human insulin on blood flow responses to endothelium-dependent and endothelium-independent vasoactive agents in vivo in normal subjects. METHODS AND
RESULTS: Ten healthy men (age: 33+/-9 years [mean+/-SD]; BMI: 23+/-2 kg/m2) were studied on two separate occasions in a double-blind, randomized, crossover fashion. In each study, blood flow responses to intrabrachial artery infusions of ACh and SNP were determined during infusion of saline and intravenously maintained normoglycemic hyperinsulinemia. Hyperinsulinemia (120 minutes; infusion rate: 1 mU/kg per minute) was created by infusing either insulin glargine or human regular insulin. Glargine and human regular insulin similarly stimulated whole-body glucose metabolism and suppressed serum free-fatty acid (FFA) concentrations. Endothelium-independent blood flow responses to low (3 microg/min) and high (10 microg/min) doses of SNP were unaffected by insulin glargine (12.2+/-2.6 versus 13.4+/-4.6 and 19.1+/-4.2 versus 19.6+/-5.1 mL/dL per minute, saline versus insulin, low- and high-dose) and regular human insulin (11.2+/-3.4 versus 12.0+/-5.2 and 16.8+/-5.7 versus 18.4+/-7.7 mL/dL per minute, respectively). In contrast, endothelium-dependent blood flow responses to low (7.5 microg/min) and high (15 microg/min) doses of ACh increased significantly and similarly by insulin glargine, 13.9+/-4.8 versus 19.3+/-6.5 mL/dL per minute (saline versus insulin, +39%, P<0.01) for low-dose ACh and 17.3+/-6.3 versus 23.2+/-9.2 mL/dL per minute (+34%; P<0.02) for high-dose ACh, and regular human insulin, 11.5+/-6.0 versus 15.8+/-8.0 mL/dL per minute (+38%; P<0.05) and 14.0+/-7.5 versus 21.1+/-10.4 mL/dL per minute (+51%; P<0.01).
CONCLUSIONS: Insulin glargine and regular human insulin have similar acute stimulatory effects on endothelium-dependent vasodilation in humans.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14656737     DOI: 10.1161/01.ATV.0000110444.59568.56

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  4 in total

1.  Insulin Enhances Endothelial Function Throughout the Arterial Tree in Healthy But Not Metabolic Syndrome Subjects.

Authors:  Linda A Jahn; Lee Hartline; Nagashree Rao; Brent Logan; Justin J Kim; Kevin Aylor; Li-Ming Gan; Helena U Westergren; Eugene J Barrett
Journal:  J Clin Endocrinol Metab       Date:  2016-01-12       Impact factor: 5.958

2.  Insulin glargine reduces carotid intimal hyperplasia after balloon catheter injury in Zucker fatty rats possibly by reduction in oxidative stress.

Authors:  Subramanyam N Murthy; Sergiy Sukhanov; Jennifer McGee; Joel A Greco; Surabhi Chandra; Patrice Delafontaine; Philip J Kadowitz; Dennis B McNamara; Vivian A Fonseca
Journal:  Mol Cell Biochem       Date:  2009-04-10       Impact factor: 3.396

3.  Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly.

Authors:  A J Varewijck; J A M J L Janssen; M Vähätalo; L J Hofland; S W J Lamberts; H Yki-Järvinen
Journal:  Diabetologia       Date:  2012-01-10       Impact factor: 10.122

Review 4.  DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs.

Authors:  Jianqiang Zhang; Qiuyue Chen; Jixin Zhong; Chaohong Liu; Bing Zheng; Quan Gong
Journal:  Front Immunol       Date:  2019-05-09       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.